Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
The Effect of Melatonin as an Adjuvant Therapy on COVID-19: A Randomized Clinical Trial
Davoodian et al., SSRN, doi:10.2139/ssrn.3878090 (Preprint), IRCT20200408046988N1
Davoodian et al., The Effect of Melatonin as an Adjuvant Therapy on COVID-19: A Randomized Clinical Trial, SSRN, doi:10.2139/ssrn.3878090 (Preprint), IRCT20200408046988N1
Jul 2021   Source   PDF  
  All Studies   Meta
RCT 81 hospitalized patients in Iran, showing significantly improved oxygen saturation with treatment. Melatonin 3mg, 3x daily for 2 weeks.
Davoodian et al., 1 Jul 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, preprint, 6 authors, trial IRCT20200408046988N1.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Abstract: Trial iew ed The effect of melatonin as an adjuvant therapy on COVID-19: A Randomized Clinical Najmeh Davoodian1,2, *, Farnoosh Sharifimood1, Davoud Salarbashi2,3,**, Sepideh Elyasi4,**, Amir Baniasad5,**, Farhang Soltani Bejestani6 1Department of Internal Medicine, Clinical Research Development Unit, Bohlool Hospital, Gonabad University of Medical Sciences, Gonabad, Iran. Diseases Research Centre, Gonabad University of Medical Sciences, Gonabad, Iran. 3Department ev 2Infectious of Nutrition and food science, School of Medicine, Gonabad University of Medical 4Department er r Sciences, Gonabad, Iran. of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. of Internal Medicine, School of Medicine, Kerman University of Medical Sciences, pe 5Department Kerman, Iran. 6Department of Rheumatology, Faculty of Medicine, Gonabad University of Medical Sciences, ot Gonabad, Iran tn *Corresponding to: Department of Internal Medicine, Gonabad University of Medical Sciences, Gonabad, Iran. Email: Pr ep rin **Co-corresponding author This preprint research paper has not been peer reviewed. Electronic copy available at: iew ed Summary Background: Melatonin is secreted by the pineal gland and has antioxidant and anti-inflammatory properties. So, it is proposed to be effective in the management of Coronavirus disease 2019 (COVID-19). This study aimed to evaluate the effect of melatonin as adjunctive therapy for the treatment of hospitalized patients with mild to moderate COVID-19. ev Methods: In this double-blind randomized placebo controlled clinical trial, 81 mild to moderate hospitalized COVID-19 patients with inclusion criteria were randomly divided to treatment (n=42) group to receive melatonin tablet 3 mg, three times daily for 2 weeks or placebo (n=39) group. Patients’ symptoms and laboratory data were er r assessed at baseline and during the follow-up period and compared between two groups. Findings: After two weeks of follow-up, the oxygen saturation and the respiratory rate significantly improved in the melatonin group. Moreover, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), Ferritin, and D-Dimer levels significantly decreased in the melatonin group, but there was a considerable increase in the placebo group. Between-group comparison showed a pe significant difference between melatonin and placebo groups. Interpretation: the results of this randomized, double-blind, placebo-controlled trial indicated the high efficacy and safety of melatonin as an adjuvant therapy in patients with mild to moderate COVID-19 disease. Further study ot with large sample size and on other populations like severe COVID-19 is recommended. Funding: This article was sponsored by the Research Council of Gonabad University of Medical Sciences Pr ep rin tn (Gonabad, Iran) This preprint research paper has not been peer reviewed. Electronic copy available at: iew ed
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop